| Product Name | Compound CK |
|---|---|
| CAS | 39262-14-1 |
| Formula | C36H62O8 |
| MW | 622.87 |
| Appearance | 白色粉末 |
| Melting point | 181-183 °C |
| Boiling point | 723.1±60.0 °C | Condition: Press: 760 Torr |
| PKa | 12.94±0.70 | Condition: Most Acidic Temp: 25 °C |
| Product Name | Compound CK |
|---|---|
| CAS | 39262-14-1 |
| Formula | C36H62O8 |
| MW | 622.87 |
| Appearance | 白色粉末 |
| Melting point | 181-183 °C |
| Boiling point | 723.1±60.0 °C | Condition: Press: 760 Torr |
| PKa | 12.94±0.70 | Condition: Most Acidic Temp: 25 °C |
WKQ-0000459
中文名稱：人參皂苷CK
中文別名：20(S)-人參皂苷CK；人參皂苷C-K；人參皂苷K；20(S)-人參皂苷C-K；(2S,3R,4S,5S,6R)-2-(((S)-2-((3S,5R,8R,9R,10R,12R,13R,14R,17S)-3,12-二羥基-4,4,8,10,14-五甲基十六氫-1H-環(huán)戊二稀并[a]菲-17-基)-6-甲基庚-5-烯-2-基)氧基)-6-(羥甲基)四氫-2H-吡喃-3,4,5-三醇
英文名稱：Compound CK
英文別名：(3β,12β)-3,12-Dihydroxydammar-24-en-20-yl β-D-glucopyranoside;20(S)-Protopanaxadiol 20-O-D-glucopyranoside;20(S)-Protopanaxadiol 20-O-β-D-glucopyranoside;20-O-β-D-Glucopyranosyl-20(S)-protopanaxadiol;20-O-β-Glucopyranosyl-20(S)-protopanaxadiol;20S-Protopanaxadiol 20-O-β-D-glucopyranoside;3-O-Deglucosylginsenoside F2;Compound k;Ginsenoside C-K;Ginsenoside IH901;Ginsenoside K;Ginsenoside M1;Ginsenoside compound K;Ginsenoside metabolite M1;IH 901;LCHK 168;NT3 VAN SC6;Protopanaxadiol 20-O-glucoside;
分子式：C36H62O8
分子量：622.87
CAS號：39262-14-1
純度：HPLC≥98%
熔點：181-183 °C
沸點：723.1±60.0 °C | Condition: Press: 760 Torr
密度：1.19±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數(shù)：12.94±0.70 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規(guī)格：5mg10mg20mg50mg100mg500mg1g2g等應(yīng)客戶需求包裝
供應(yīng)單位：四川省維克奇生物科技有限公司
供應(yīng)電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產(chǎn)中藥類標準品和天然植物有效單體，主打中藥對照品/標準品/天然植物有效單體，化學合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關(guān)注！ 新批次有現(xiàn)貨，歡迎咨詢。
| Ginsenoside compound K exerts antitumour effects in renal cell carcinoma via regulation of ROS and lncRNA THOR | ||
| Source:SCI：ONCOLOGY REPORTS | Author:Shuqiu Chen | Notes：影響因子：3.906 |
| Reference description | ||
All cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) with 10% heat-inactivated foetal bovine serum (FBS; HyClone; Cytiva), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich; Merck KGaA) at 37°C in a humidified 5% CO2 atmosphere. CK was purchased from Sichuan WeiKeqi Biological Technology Co., Ltd. Pan-caspase inhibitor z-VAD was obtained from Sigma-Aldrich (Merck KGaA) and was used at a concentration of 10 μM at 37°C. | ||
| Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair | ||
| Source:SCI：PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR | Author:Hualin Zhang | Notes：影響因子：2.781 |
| Reference description | ||
The ginsenoside Rb3 (Rb3) was isolated from SCLPN, and its structure was characterized by spectroscopic analysis with both ESI-MS and 13C NMR. 20(S)-Ginsenoside Rg3 (Rg3, Lot No.: 14,197–60-5-15-1), 20(S)-ginsenoside Rh2 (Rh2, Lot No.: 78214-33-2-14-6), compound K (C-K, Lot No.: 39262-14-1-14-9) and 20(S)-protopanaxadiol (PPD, Lot No.: 30636-90-9-14-2) were supplied by Sichuan Weikeqi Biological Technology Co. Ltd. (Chengdu, China). These compounds are white powders with a purity of 98%, which was verified by high | ||
| Effects of compound K, a metabolite of ginsenosides, on memory and cognitive dysfunction in db/db mice involve the inhibition of ER stress and the NLRP3 inflammasome pathway | ||
| Source:SCI：Food & Function | Author:Chu-Wen Li | Notes：影響因子：4.171 |
| Reference description | ||
Ginsenoside compound K (CK, purity: UV ≥ 98%) was obtained from Weikeqi Biological Technology (Sichuan, China), while sodium carboxymethylcellulose (CMCNa), glucose and insulin solutions were acquired from Sigma-Aldrich (MO, USA) | ||
| Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer | ||
| Source:SCI：PHARMACEUTICAL BIOLOGY | Author:Keqiang Zhang | Notes：影響因子：1.241 |
| Reference description | ||
CK (purity?>?98%) was provided by Weikeqi Biological Technology Co. (Shichuan, China). DDP was purchased from Haosen Pharmaceutical Co., Ltd. (Jiangsu, China). | ||
| Structure–inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs) | ||
| Source:SCI：TOXICOLOGY AND APPLIED PHARMACOLOGY | Author:Zhong-Ze Fang | Notes：影響因子：3.975 |
| Reference description | ||
Recombinant human UGT isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, UGT2B15) expressed in baculovirus-infected insect cells were obtained from BD Gentest Corp. (Woburn, MA, USA). Ginsenosides Rb1, Rb2, Rc, Rd, Rg3, Rh2, C-K, ppd, ppt, Re, Rg1, Rh1, F1, and F2 were purchased from Sichuan Weikeqi Biotechnology Company (Chengdu, Sichuan, China). The purity of these compounds was above 95%. All other reagents were of HPLC grade or of the highest grade commercially available. | ||
| Effect of steam-processing of the Panax ginseng root on its inducible activity on granulocyte-colony stimulating factor secretion in intestinal epithelial cells in vitro | ||
| Source:SCI：JOURNAL OF ETHNOPHARMACOLOGY | Author:Kewen Ding | Notes：影響因子：4.36 |
| Reference description | ||
Isomaltose was purchased from Tokyo Chemical Industry (Tokyo, Japan). Protopanaxatriol and protopanaxadiol were obtained from ChromaDex (Irvine, CA). Compound K, ginsenosides Rh1, Rd, F1, F2, Rg3, and Rh2 were obtained from Sichuan Weikeqi Biological Technology (Chengdu, Sichuam, China). Lectin from Phytolacca americana (pokeweed mitogen, PWM), dextran standards certified according to Deutsches Institut für Normung (molecular weight; 668 kDa), Dulbecco’s modified Eagle’s medium | ||
